Jason Lettmann, ALX Oncology CEO
July 31, 2024 04:01 PM EDT
R&D

ALX On­col­o­gy con­tin­ues its CD47 quest, re­veal­ing Phase 2 gas­tric can­cer da­ta

Max Gelman

Senior Editor

ALX On­col­o­gy re­leased topline re­sults from a Phase 2 gas­tric can­cer tri­al, build­ing on an in­ter­im read­out from late last year that left a glim­mer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times